Biocon

Bengaluru, India Founded: 1978 • Age: 48 yrs Listed Fortune India 500 · #172
Drug RD services are provided for multiple therapeutic areas.
Request Access
Report Incorrect Data
Page last updated

About Biocon

Biocon is a publicly listed company based in Bengaluru (India) founded in 1978 by Kiran Mazumdar Shaw. Drug RD services are provided for multiple therapeutic areas. Biocon has raised $6.88 million across 12 funding rounds from investors including Goldman Sachs, Kotak Mahindra Bank and Tata Capital Growth Fund. The company has 3,269 employees. Biocon has completed 2 acquisitions, including Axicorp and Nobex Corp. Its chief executive, as recorded, is Siddharth Mittal. Its website biocon.com draws about 82 thousand monthly visits. Its Indian entity Biocon Limited reported revenue of ₹2,666 Cr. Biocon offers products and services including Biosimilars and Generics. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

Biocon was founded in 1978 in Bengaluru, India, within the biotechnology sector. Drug research and development services are offered across various therapeutic areas. Additional operations include research on gene therapy, API development, generic formulations, quality control, and scientific services. The company supports pharmaceutical innovation through these specialized offerings in the Indian market.

Biocon is ranked #172 on the Fortune India 500 (2025).

Recognitions & Rankings of Biocon

Fortune India 500 2025 edition
Rank#172
Total income
₹16,272 Cr
Profit
₹1,013 Cr
Last year #154
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#140
Valuation
₹44,360 Cr
2023 #162 2022 #129 2021 #103
  • Headquarters Bengaluru, India
  • Employees 3,269
  • Founders Kiran Mazumdar Shaw
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Pharmacy
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website biocon.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Biocon Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹59,981 Cr

    BIOCON · NSE

  • Share Price
    ₹369.65

    +0.43% today

  • Revenue
    ₹16,927 Cr

    FY 2025-26 · +10.9% YoY

  • EBITDA
    ₹3,052 Cr

    Margin 18.0%

  • Net Profit
    ₹389 Cr

    FY 2025-26 · -59.3% YoY

  • P/E (TTM)
    88.1x

    P/B 1.7x

  • ROE
    1.3%

    ROCE 3.8%

  • Debt / Equity
    0.61

    Interest cover 90.4x

  • Total Equity Funding
    $6.88M (USD)

    in 12 rounds

  • Latest Funding Round
    $459.77M (USD), Post-IPO

    Jan 2026

  • Investors
    Goldman Sachs

    & 15 more

  • Employee Count
    3,269
  • Investments & Acquisitions
    Axicorp

    & 1 more

Products & Services of Biocon

Biocon offers a comprehensive portfolio of products and services, including Biosimilars and Generics.

Biosimilars
Biopharmaceuticals

Biosimilars are developed as cost-effective alternatives to biologic drugs for various therapeutic areas

Generics
Generic Drugs

Generics are manufactured for key therapeutic areas to provide affordable medication options

Apps and channels of Biocon

its YouTube channel Biocon Limited has 5.84K subscribers and 30 videos.

Biocon Limited
YouTube 5.84K subscribers 30 videos Science & Technology
Open channel

Videos from Biocon

The most watched videos on Biocon's YouTube channel, Biocon Limited (5.84K subscribers). Click a video to play it here.

Biocon Anthem: A Tribute by Bioconites to Our Legacy and Unity !
4.2K views
Kiran Mazumdar - Shaw, Executive Chairperson, Biocon & Biocon Biologics speaking on Q3 FY24 Results
1.9K views
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics speaking on Q4 & FY24 Results
1.5K views
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics speaking on Q1 FY25 Results
1.2K views

More on Biocon Limited.

Funding Insights of Biocon

Biocon has successfully raised a total of $6.88M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $459.77 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $6.88M
  • Total Rounds 12
  • Last Round Post-IPO — $459.77M
  • First Round $3.44M

    (Mar 2000)

  • Investors Count 16

Latest 10 of 12 funding rounds of Biocon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2026$459.77MPost-IPO––
SBI Mutual Fund, ICICI Prudential Asset Management Company
Jun 2025$520.48MPost-IPO––
ICICI Prudential Asset Management Company, SBI Mutual Fund
Apr 2023$300MPost-IPO––
Serum Life Sciences
Feb 2023$129.21MPost-IPO––
Kotak Mahindra Bank
Jan 2021$75.83MPost-IPO––
ADQ
Nov 2020$150MPost-IPO––
Goldman Sachs
Jul 2020$30.1MPost-IPO––
Tata Capital Growth Fund
Jan 2020$100MPost-IPO––
True North
May 2003Private Equity Round–True North
–
Aug 2000Unspecified––
–
Valuation history

16 investors in total: 16 institutional.

Investors in Biocon

Biocon has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, Kotak Mahindra Bank and Tata Capital Growth Fund.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
ADQ
ADQ is recognized as a leading sovereign investor focused on sustainable economic transformation in Abu Dhabi.
adq.aeAbu Dhabi, United Arab Emirates
Goldman Sachs
Investment banking services are delivered across multiple financial sectors.
1869goldmansachs.comNew York, United States
Tata Capital Growth Fund
Growth capital fund sponsored by the Tata group, focusing on investments and portfolio management.
2022tatacapitalgrowthfund.comMumbai, India
True North
Private equity is invested by True North in mid-market companies.
truenorth.co.inMumbai, India
Mirae Asset
miraeassetmf.co.in
ICICI Venture
iciciventure.com
Nippon India Mutual Fund
nipponindiaim.com
Serum Life Sciences
Develops innovative vaccine technologies for infectious diseases.
2020silsuk.comLondon, United Kingdom
Kotak Mahindra Bank
Commercial banking services are offered to corporate and retail customers.
1985kotak.comMumbai, India
SBI Mutual Fund
sbimf.com
Premium access

Investor details for Biocon

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Biocon Limited (Biocon)

Biocon Limited is the primary company behind Biocon. The board of Biocon Limited currently have 13 directors; the longest-serving is Ravi Rasendra Mazumdar, appointed in 2000. 22 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ravi Rasendra Mazumdar
DIN 00109213
Director08 Aug 200026 yrs 3 moBiocon Limited
Kiran Mazumdar Shaw
DIN 00347229
Whole-time director01 Apr 201016 yrs 7 moBiocon Limited
Eric Vivek Mazumdar
DIN 09381549
Director01 Nov 20215 yrsBiocon Limited
Naina Lal Kidwai
DIN 00017806
Director28 Apr 20224 yrs 6 moBiocon Limited
Rekha Mehrotra Menon
DIN 02768316
Director26 Jul 20233 yrs 3 moBiocon Limited
Atul Dhawan
DIN 07373372
Director16 May 20242 yrs 5 moBiocon Limited
Shreehas Pradeep Tambe
DIN 09796480
Managing Director01 Apr 20267 moBiocon Limited
Daniel Mark Bradbury
DIN 06599933
Director01 Aug 20263 moBiocon Limited
Rajiv Malik
DIN 00120557
Director01 Aug 20263 moBiocon Limited
Nivruti Rai
DIN 01353079
Director01 Aug 20263 moBiocon Limited
Peter Baron Piot
DIN 09015343
Director01 Aug 20263 moBiocon Limited
Thomas Jason Roberts
DIN 09337723
Director01 Aug 20263 moBiocon Limited
Arun Suresh Chandavarkar
DIN 01596180
Director01 Aug 20263 moBiocon Limited

People of Biocon

138 people are tracked at Biocon (50 in leadership, 7 in board & advisors, 81 in team); the tracked headcount is 3,269.

NameRoleGroup
Kiran Mazumdar Shaw
FounderLeadership
Siddharth Mittal
CEO & Managing DirectorLeadership
Jacqueline Paiva
Head MarketingLeadership
Akhbar Muhamad
Director - SCM WarehouseLeadership
Ganesh Ramachandran
Head-peptide PurificationLeadership
Maninder Kapoor Puri
Head Of Human ResourcesLeadership
Hari Ranjan Prasad
Associate Director- Corporate StrategyLeadership
Girish Deshpande
Head-ard (peptide & Fermentation Api)Leadership
Arun Gupta
Chief Operating OfficerLeadership
Amit Kaptain
Head - Global API Business & FDF Emerging MarketsLeadership
Lakshminarayanan S
Site Head - API OperationsLeadership
Prasad V J V
Head Site QA API (site-6)Leadership
Christiane Hamacher
CEO, Biocon Biologics India LimitedLeadership
Hiteshwar Pruthi
Senior Director, Country Lead - GermanyLeadership
Trisha Durant
Head, Europe - Commercial Strategy & Business Dev.Leadership
Pravin Kumar Arora
Cluster Head - API OperationsLeadership
Dr. Rakesh Bhasin
Head R&d (formulations )Leadership
Pramod Kumar
Senior Director - Head Distribution And LogisticsLeadership
Swapnil J.
VP & Head, Corporate Strategy At Biocon LimitedLeadership
Anil S.
Vice President And Global Head Of Regulatory AffairsLeadership

118 more people are available in the full profile.

Premium access

Complete people profiles for Biocon

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Biocon

Biocon is a publicly listed company on the NSE with ticker symbol BIOCON in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date07 Apr 2004
  • Listed onBSE: 532523 · NSE: BIOCON
  • Listed entityBiocon Limited
  • Exchange sectorHealth technology
  • ISININE376G01013
  • Share price₹350.60 (-0.11% on the day) · 2026-10-14
  • Market capitalisation₹57,155 Cr
  • Price to earnings104.3
  • EPS (diluted, trailing year)₹3.36
  • Dividend yield0.14%
  • Volume (last session)3,375,305

Financials of Biocon

Exchange-reported figures of Biocon Limited, the listed company behind Biocon (NSE: BIOCON).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹16,927 Cr
+10.9% YoY
EBITDA
₹3,052 Cr
-3.6% YoY
Profit After Tax
₹389 Cr
-59.3% YoY
Net Worth
₹34,032 Cr
+57.2% YoY
Total Assets
₹53,490 Cr
+8.0% YoY
Total Debt
₹15,434 Cr
-15.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16,92715,26214,75611,1748,1847,1436,300
Revenue growth+10.9%+3.4%+32.1%+36.5%+14.6%+13.4%-
EBITDA3,0523,1663,2032,0531,6521,5731,574
EBITDA margin+18.0%+20.8%+21.7%+18.4%+20.2%+22.0%+25.0%
Profit before tax4481,8871,5258979831,0681,186
Net profit389956978693747730690
Net profit margin+2.3%+6.3%+6.6%+6.2%+9.1%+10.2%+11.0%
EPS (₹)2.388.448.523.855.406.176.24
Balance sheet
Total assets53,49049,52343,17245,67017,44015,68511,816
Net worth34,03221,64419,78417,8678,4327,6276,706
Total debt15,43418,36216,27718,0195,1474,4812,715
Cash & bank3,1944,1202,2592,4001,7482,015999
Net working capital6,5726,9232,3575,0164,2633,5871,869
Cash flow
Cash from operations1,9944,0612,9541,8521,1771,1601,283
Cash from investing(1,883)(203)(1,002)(14,260)(1,662)(3,651)(1,505)
Cash from financing(924)(1,854)(2,333)13,0492422,564388
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,3894,3364,5174,1734,2963,9424,4173,821
Revenue growth (YoY)+2.2%+10.0%+2.3%+9.2%+19.6%+14.8%--
Other income34.5054.5052.5011793.0079.7057.3052.90
EBITDA8248349405408247491,078752
EBITDA margin+19.0%+19.4%+21.0%+13.1%+19.3%+19.2%+24.7%+19.9%
Depreciation564547513515473455436425
Interest240213232210272277212223
Profit before tax54.80128248(67.80)17196.90487156
Tax(1.90)(9.20)48.90(16.00)38.507.7027.4074.80
Net profit56.70137199(51.80)13389.2045981.10
EPS (₹)0.250.870.791.070.650.262.870.21
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,3462,2432,1271,9931,7382,0281,988
Revenue growth+4.6%+5.4%+6.7%+14.7%-14.3%+2.0%-
EBITDA11.0017626323.5061.10312286
EBITDA margin+0.5%+7.8%+12.4%+1.2%+3.5%+15.4%+14.4%
Profit before tax51.006611502,971140359553
Net profit175(50.81)106(13.33)83.18278305
Net profit margin+7.5%-2.3%+5.0%-0.7%+4.8%+13.7%+15.3%
EPS (₹)0.235.070.9923.720.722.343.67
Balance sheet
Total assets28,35714,49213,07812,3338,2798,0247,584
Net worth27,08011,52410,91210,9168,0937,9077,537
Total debt1,1532,8762,0431,30176.901.904.00
Cash & bank91.70250586720689601375
Net working capital1,2101,0552,0071,5481,5501,2801,218
Cash flow
Cash from operations(180)624(123)21947.60478387
Cash from investing(6,580)(992)(295)(1,173)(302)(628)(189)
Cash from financing6,6024953441,03911227.80(129)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue630624605621583537644563
Revenue growth (YoY)+8.1%+16.3%-6.1%+10.4%+11.0%+5.2%--
Other income90.7064.8049.8074.8013461.3062.70672
Total expenses541564544744530516582532
EBITDA89.2060.8060.50(123)52.9020.6062.0031.30
EBITDA margin+14.1%+9.7%+10.0%-19.8%+9.1%+3.8%+9.6%+5.6%
Depreciation38.2038.4036.2034.0033.8033.3033.0033.80
Interest21.9017.3016.702.3067.2056.2056.7065.30
Profit before tax12069.9057.40(84.50)85.70(7.60)35.00604
Tax28.1017.706.40(8.10)14.800.7013.8019.90

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,3894,3364,5174,1734,2963,9424,4173,821
Revenue growth (YoY)+2.2%+10.0%+2.3%+9.2%+19.6%+14.8%--
Other income34.5054.5052.5011793.0079.7057.3052.90
EBITDA8248349405408247491,078752
EBITDA margin+19.0%+19.4%+21.0%+13.1%+19.3%+19.2%+24.7%+19.9%
Depreciation564547513515473455436425
Interest240213232210272277212223
Profit before tax54.80128248(67.80)17196.90487156
Tax(1.90)(9.20)48.90(16.00)38.507.7027.4074.80
Net profit56.70137199(51.80)13389.2045981.10
EPS (₹)0.250.870.791.070.650.262.870.21
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16,92715,26214,75611,1748,1847,1436,300
Revenue growth+10.9%+3.4%+32.1%+36.5%+14.6%+13.4%-
Other income3421,305866376213267229
Total expenses13,87512,09511,5539,1216,5325,5704,726
Employee cost3,5083,1442,6642,1811,8801,7411,459
EBITDA3,0523,1663,2032,0531,6521,5731,574
EBITDA margin+18.0%+20.8%+21.7%+18.4%+20.2%+22.0%+25.0%
Depreciation1,9571,6871,5691,113814715552
Interest99089797441967.6057.7064.90
Profit before tax4481,8871,5258979831,0681,186
Tax79.10457227254212222315
Net profit389956978693747730690
Net profit margin+2.3%+6.3%+6.6%+6.2%+9.1%+10.2%+11.0%
EPS (₹)2.388.448.523.855.406.176.24
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital810600600600600600600
Reserves & surplus33,32921,12219,18317,2677,8327,0276,106
Shareholders' funds (net worth)34,03221,64419,78417,8678,4327,6276,706
Minority interest2,5906,0685,4914,6221,038881677
Secured loans11,29312,70112,23013,7952,6222,2952,042
Unsecured loans4,1415,6614,0474,2242,5252,186674
Total debt15,43418,36216,27718,0195,1474,4812,715
Total liabilities53,49049,52343,17245,67017,44015,68511,816
Assets
Gross block48,07940,80437,93035,32111,23310,2219,147
Net block36,48631,96330,64429,4686,5696,3645,971
Capital work in progress6,9878,5087,9937,3174,1102,8002,196
Investments1,7791,1271,0002,0691,5881,952966
Inventories6,0864,9314,9444,2442,2981,8671,436
Sundry debtors5,9875,4886,2313,5732,0581,5031,224
Cash & bank balances3,1944,1202,2592,4001,7482,015999
Loans & advances1,2241,3001,4307901,0611,006809
Total current assets16,49015,83914,86411,0087,1656,3924,467
Total current liabilities9,9188,91612,5075,9922,9012,8052,598
Net working capital6,5726,9232,3575,0164,2633,5871,869
Total assets53,49049,52343,17245,67017,44015,68511,816
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,9249201,300654897825659
Net cash from operating activities1,9944,0612,9541,8521,1771,1601,283
Net cash from investing activities(1,883)(203)(1,002)(14,260)(1,662)(3,651)(1,505)
Net cash from financing activities(924)(1,854)(2,333)13,0492422,564388
Net change in cash(812)2,004(380)641(243)72.30165
Closing cash3,1944,1202,2592,4001,7482,015999
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.9%+3.4%+32.1%+36.5%+14.6%+13.4%-
EBITDA growth-3.6%-1.1%+56.0%+24.3%+5.0%-0.1%-
PBT growth-76.3%+23.7%+70.0%-8.8%-7.9%-10.0%-2.4%
Net income growth-59.3%-2.3%+41.2%-7.3%+2.4%+5.8%-
Revenue CAGR (3Y)+14.9%+23.1%+27.4%+21.1%+14.1%+20.1%+17.4%
EBITDA CAGR (3Y)+14.1%+24.2%+26.7%+9.3%+5.8%+23.8%+17.1%
Profitability & leverage
Net income margin+2.2%+9.4%+8.8%+5.8%+9.4%+11.9%+13.8%
Return on capital employed+3.8%+6.9%+6.4%+5.7%+7.6%+8.7%+12.2%
Return on net worth+1.3%+6.9%+6.9%+6.6%+10.8%+11.8%+13.6%
Debt / equity0.610.840.910.880.600.500.40
Long-term debt / equity0.460.670.770.750.500.400.32
Interest cover90.3860.6659.6344.568.076.726.35
Efficiency & per share
Fixed asset turnover0.380.390.400.480.760.740.78
Inventory turnover3.073.093.213.423.934.335.11
Debtors turnover2.952.603.013.974.605.245.01
EPS (₹)2.388.448.523.855.406.176.24
Dividend per share (₹)0.500.500.501.500.500.000.00
Book value per share (₹)210.60180.92164.77148.8170.2363.5555.87
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue630624605621583537644563
Revenue growth (YoY)+8.1%+16.3%-6.1%+10.4%+11.0%+5.2%--
Other income90.7064.8049.8074.8013461.3062.70672
Total expenses541564544744530516582532
EBITDA89.2060.8060.50(123)52.9020.6062.0031.30
EBITDA margin+14.1%+9.7%+10.0%-19.8%+9.1%+3.8%+9.6%+5.6%
Depreciation38.2038.4036.2034.0033.8033.3033.0033.80
Interest21.9017.3016.702.3067.2056.2056.7065.30
Profit before tax12069.9057.40(84.50)85.70(7.60)35.00604
Tax28.1017.706.40(8.10)14.800.7013.8019.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,3462,2432,1271,9931,7382,0281,988
Revenue growth+4.6%+5.4%+6.7%+14.7%-14.3%+2.0%-
Other income3208502083,134187150366
Total expenses2,3352,0671,8651,9691,6771,7161,702
Employee cost467501452434368390345
EBITDA11.0017626323.5061.10312286
EBITDA margin+0.5%+7.8%+12.4%+1.2%+3.5%+15.4%+14.4%
Depreciation13712812111710810498.00
Interest14223719969.600.400.401.20
Profit before tax51.006611502,971140359553
Tax13.8051.6031.0012353.6078.30112
Net profit175(50.81)106(13.33)83.18278305
Net profit margin+7.5%-2.3%+5.0%-0.7%+4.8%+13.7%+15.3%
EPS (₹)0.235.070.9923.720.722.343.67
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital810600600600600600600
Reserves & surplus26,23711,00210,31210,3167,4937,3076,937
Shareholders' funds (net worth)27,08011,52410,91210,9168,0937,9077,537
Secured loans1752,2522,0411,29875.900.000.00
Unsecured loans9786242.003.501.001.904.00
Total debt1,1532,8762,0431,30176.901.904.00
Total liabilities28,35714,49213,07812,3338,2798,0247,584
Assets
Gross block3,2352,8392,5872,4802,2772,0981,993
Net block1,3811,114958961870798793
Capital work in progress541701560344285179152
Investments24,97811,3839,3189,2715,2805,4134,953
Inventories875836665560542431535
Sundry debtors1,0038291,048658701588573
Cash & bank balances91.70250586720689601375
Loans & advances146255399307209210462
Total current assets2,1162,1702,6972,2452,1401,8301,945
Total current liabilities9061,115690697590550727
Net working capital1,2101,0552,0071,5481,5501,2801,218
Total assets28,35714,49213,07812,3338,2798,0247,584
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash250122197111254375306
Net cash from operating activities(180)624(123)21947.60478387
Net cash from investing activities(6,580)(992)(295)(1,173)(302)(628)(189)
Net cash from financing activities6,6024953441,03911227.80(129)
Net change in cash(158)127(74.30)85.60(142)(122)69.30
Closing cash91.70250586720689601375
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.6%+5.4%+6.7%+14.7%-14.3%+2.0%-
EBITDA growth-93.7%-33.1%+1017.9%-61.5%-80.5%+9.3%-
PBT growth-92.3%+339.7%-94.9%+2026.8%-61.1%-35.1%+2.9%
Net income growth+445.0%-148.0%+894.4%-116.0%-70.0%-8.9%-
Revenue CAGR (3Y)+5.6%+8.9%+1.6%+0.1%-0.9%-5.7%-8.4%
EBITDA CAGR (3Y)-22.4%+42.2%-5.6%-56.5%-33.8%-0.6%-21.5%
Profitability & leverage
Net income margin+1.6%+27.2%+5.6%+142.9%+5.0%+13.8%+22.2%
Return on capital employed+1.6%+2.1%+2.6%+1.5%+1.7%+4.6%+5.2%
Return on net worth+0.9%-0.5%+1.0%-0.1%+1.1%+3.6%+4.2%
Debt / equity0.100.220.150.070.000.000.01
Long-term debt / equity0.060.190.150.070.000.000.01
Interest cover-112.75493.54140.40-74.52-0.850.190.64
Efficiency & per share
Fixed asset turnover0.770.830.840.840.790.990.87
Inventory turnover2.742.993.473.623.584.202.98
Debtors turnover2.562.392.492.932.703.492.70
EPS (₹)0.235.070.9923.720.722.343.67
Dividend per share (₹)0.500.500.501.500.500.000.00
Book value per share (₹)166.8596.6390.8890.9167.4065.8862.80

Investments & Acquisitions by Biocon

Biocon has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Axicorp and Nobex Corp.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Axicorp
OTC drugs are manufactured by Axicorp in Germany.
axicorp.deFriedrichsdorf, Germany2002Feb 2008$43.5M
Nobex Corp
Blog on legal & personal attorney related topics
nobexcorp.comDurham, United States1993Apr 2006••••
Premium access

Complete acquisition details for Biocon

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Biocon

6 dated milestones of Biocon across 48 years, from founding to its latest funding, stage changes and deals.

  1. Founded Biocon is founded.
  2. Funding First funding round of $3.4M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Nobex Corp.
  5. Acquisition Acquires Axicorp.
  6. Funding Latest funding round, Post-IPO, of $459.8M.

Web traffic of Biocon

The website of Biocon (biocon.com) receives about 82.3K visits a month and ranks #297,196 among all websites worldwide, #553 in Pharmacy.

  • Monthly visits
    82.3K

    ▼ 14% vs previous month

  • Unique visitors
    31.8K

    per month

  • Global rank
    #297,196

    among all websites

  • Category rank
    #553

    Health · Pharmacy

Similar websites

Websites whose visitors overlap most with Biocon. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Pharmaceutical Technology
pharmaceutical-technology.com
100%
#316,052View details
Syngene
syngeneintl.com
91%
94K#525,515View details
Glenmark Pharmaceuticals
glenmarkpharma.com
90%
106.3K#278,385View details
Pfizer
pfizer.com
78%
1.9M#24,984View details
Hikma
hikma.com
77%
159K#227,704View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 38 similar websites and full traffic analytics for Biocon

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 38 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Biocon (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Biocon

Biocon: Kotak Institutional Equities on Biocon upgrades to Add, Target Price Rs 390; Q2FY27 missed estimates due to deferred biosimilar shipments and slower generics growth, although management continues to expect a strong second half led by recent biosimilar launches. Kotak expects 15% biosimilars sales CAGR and 17% EBITDA CAGR over FY26–29, supported by market-share gains, new launches, insulin capacity expansion, improved growth and debt reduction. Recent stock price correction has improved the risk-reward.
Exchange Update • 7 days ago
BIOCON: Q2 EBITDA 8.3B RUPEES VS 8.35B (YOY); Q2 EBITDA MARGIN 18.9% VS 19.45% (YOY)
Exchange Update • 8 days ago
BIOCON: Q2 CONS NET PROFIT 413M RUPEES VS 845M (YOY); EST 1.65B
Exchange Update • 8 days ago
BIOCON: Q2 REVENUE 44B RUPEES VS 42.95B (YOY)
Exchange Update • 8 days ago
Biocon: First Half FY27 Achievements Build A Solid Base For A Robust Second Half, Adding More Insulin Production And Ongoing Regulatory And Business Advancements.
Exchange Update • 8 days ago
Biocon: Co Anticipates Stronger H2 Due To New Launches And Increased Insulin Production
Exchange Update • 8 days ago
Biocon: Company Gains Approval For Yesintek, A Biosimilar To Stelara, In New Global Markets.
Exchange Update • 17 days ago
Biocon: Company Gets Early Launch Date For Pertuzumab Biosimilar Pebrilzo, U.S. Launch Expected In Q3 CY2028.
Exchange Update • 29 days ago
BIOCON: Rs. 39.04 Crores NSE Block Trade; for ~ 1,057,554 Shares, at Rs. 369.20
Exchange Update • 1 month ago
Biocon: Biocon Malaysia Gets MHRA Approval For New Drug Product Fill Finish Unit For Insulins
Exchange Update • 1 month ago
Premium access

Complete news archive for Biocon

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Biocon on our blog

Frequently Asked Questions about Biocon

Biocon was founded in 1978 and raised its 1st funding round 22 years after it was founded.

Biocon is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Siddharth Mittal is the CEO of Biocon, as recorded in our data.

Biocon is a funded company, having raised a total of $6.88M across 12 funding rounds to date.

Biocon has 3,269 employees.

The primary company behind Biocon, Biocon Limited, reported revenue of ₹2,666 Cr for FY 2026, up 11% year on year.

Biocon was founded in 1978 in Bengaluru, India, within the biotechnology sector. Drug research and development services are offered across various therapeutic areas. Additional operations include research on gene therapy, API development, generic formulations, quality control, and scientific services. The company supports pharmaceutical innovation through these specialized offerings in the Indian market.

Biocon offers Biosimilars and Generics.

Yes, Biocon is publicly traded on NSE under the ticker symbol BIOCON.

Biocon has made 2 acquisitions, including Axicorp, and Nobex Corp.

Biocon has 16 investors. Key investors include Goldman Sachs, Kotak Mahindra Bank, Tata Capital Growth Fund, Serum Life Sciences, and ADQ.

Biocon operates through Biocon Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available